Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 4
2012 2
2013 4
2014 3
2015 5
2016 5
2017 2
2018 2
2019 2
2020 3
2021 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL.
Blumenberg V, Busch G, Baumann S, Jitschin R, Iacoboni G, Gallur L, Iraola-Truchuelo J, Hoster E, Winkelmann M, Hellwig K, Schmidt C, Frölich L, Tast B, Hildebrand F, Rejeski K, Dekorsy F, Schmidkonz C, Bäuerle T, Kunz WG, Mougiakakos D, Müller F, von Bergwelt-Baildon M, Barba P, Bücklein VL, Mackensen A, Völkl S, Subklewe M. Blumenberg V, et al. Among authors: jitschin r. Blood Adv. 2023 Nov 28;7(22):6844-6849. doi: 10.1182/bloodadvances.2023010364. Blood Adv. 2023. PMID: 37748131 Free PMC article.
Accumulation of T-cell-suppressive PD-L1high extracellular vesicles is associated with GvHD and might impact GvL efficacy.
Baur R, Karl F, Böttcher-Loschinski R, Stoll A, Völkl S, Gießl A, Flamann C, Bruns H, Schlötzer-Schrehardt U, Böttcher M, Schewe DM, Fischer T, Jitschin R, Mackensen A, Mougiakakos D. Baur R, et al. Among authors: jitschin r. J Immunother Cancer. 2023 Mar;11(3):e006362. doi: 10.1136/jitc-2022-006362. J Immunother Cancer. 2023. PMID: 36898735 Free PMC article.
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib.
Häselbarth L, Karow A, Mentz K, Böttcher M, Roche-Lancaster O, Krumbholz M, Jitschin R, Mougiakakos D, Metzler M. Häselbarth L, et al. Among authors: jitschin r. Cancer Immunol Immunother. 2023 Jun;72(6):1661-1672. doi: 10.1007/s00262-022-03361-8. Epub 2023 Jan 5. Cancer Immunol Immunother. 2023. PMID: 36602564 Free PMC article.
32 results